Toru Ishikawa
A5073095975- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Natural product bioactivities and synthesis
- Phytochemistry and Biological Activities
- Pancreatic and Hepatic Oncology Research
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Plant chemical constituents analysis
- Plant biochemistry and biosynthesis
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Organ Transplantation Techniques and Outcomes
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Pancreatitis Pathology and Treatment
- Liver physiology and pathology
- Abdominal vascular conditions and treatments
- Biological Activity of Diterpenoids and Biflavonoids
- Gastrointestinal disorders and treatments
- Lung Cancer Research Studies
Saiseikai Niigata Daini Hospital
2016-2025
Yokohama National University
2024
Toyama University Hospital
2023-2024
Second Affiliated Hospital of Xi'an Jiaotong University
2024
Kaohsiung Medical University
2024
National Sun Yat-sen University
2024
University of Oxford
2023
Nippon Medical School
2022
Tokyo Women's Medical University
2018-2021
Keio University
2018-2021
<b><i>Background/Aim:</i></b> The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing Japan along the progression antiviral therapies and aging society. We evaluated usefulness modified albumin-bilirubin (ALBI) grade as a tool for assessment function. <b><i>Materials/Methods:</i></b> enrolled 6,649 naïve HCC treated from 2000 to 2017 divided them into training (Ehime Prefecture group: E...
Aim/Background: The purpose of this study was to evaluate the validity 3 classifications for assessing liver function, damage and Child-Pugh newly proposed albumin-bilirubin (ALBI) grade, in order examine feasibility evaluating hepatic function using ALBI grade with hepatocellular carcinoma (HCC) treatment algorithm used Japan. Methods: We analyzed medical records 3,495 Japanese HCC patients admitted from 2000 2015, which were comprised 1,580 hospitalized Ehime Prefecture area as a training...
We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u-HCC) by investigating real-world clinical features of patients.
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
<b><i>Introduction:</i></b> Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE common. The present phase 2, prospective, multicenter, single-arm trial, TACTICS-L investigated efficacy and safety of plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization has better objective response rate (ORR) than sorafenib (jRCTs031180074)....
<b><i>Background/Aim:</i></b> We evaluated the relationship of hepatic function with repeated transarterial catheter chemoembolization (TACE) and prognosis after sorafenib treatment in various patient cohorts. <b><i>Methods:</i></b> Study 1 comprised 212 Barcelona clinic liver cancer stage-B (BCLC-B) HCC patients classified as Child-Pugh A (CP-A) who had received TACE treatments (r-TACE) (naïve:recurrence = 66:146). 2 435 unresectable CP-A was...
Abstract Background/Aim Presently, there are no therapeutic options for unresectable hepatocellular carcinoma (u‐HCC) patients who intolerant to sorafenib or regorafenib failure. There have been reports with detailed clinical findings of lenvatinib (LEN), a newly developed first‐line tyrosine kinase inhibitor (TKI), obtained in real‐world practice. We aimed elucidate the efficacy LEN. Materials/Methods From March August 2018, 105 u‐HCC were treated Following exclusion those started reduced...
Background & AimsPlatelet transfusion is used to prevent hemorrhagic events in patients with thrombocytopenia undergoing invasive procedures, but there are many disadvantages. We evaluated the efficacy and safety of lusutrombopag chronic liver disease procedures.MethodsWe performed a double-blind, parallel-group, phase 3 study 96 (platelet counts below 50,000/μL) procedures from October 2013 May 2014 at 81 centers Japan. Patients were randomly assigned (1:1) groups given once-daily (3 mg) or...
Abstract Background To assess the recent real-world changes in etiologies of liver cirrhosis (LC) Japan, we conducted a nationwide survey annual meeting Japan Society Hepatology (JSH). Methods We investigated LC patients accumulated from 68 participants 79 institutions ( N = 48,621). next assessed changing trends by analyzing cases which year diagnosis was available 45,834). further evaluated transition real number newly identified assessing data 36 hospitals with complete datasets for...
Lenvatinib (LEN) has recently become available as a first-line tyrosine-kinase inhibitor (TKI) for unresectable hepatocellular carcinoma (u-HCC). In patients who showed intolerability or failure in other TKI treatments, alternative treatment options are needed. This retrospective study evaluated the therapeutic potential of LEN clinical practice.We enrolled 57 u-HCC treated with from March to June 2018. was given orally weighing <60 kg at 8 mg/day and 12 those ≥60 kg. Following exclusion...
We evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN).We enrolled 84 u-HCC cases TKIs LEN from March 2018 January 2019 (median age 71 years, 63 males, Child-Pugh score (CPS) 5/6/7 = 62/21/1, tumor-node-metastasis stage Liver Cancer Study Group Japan 6th (TNM-LCSGJ) II/III/IVa/IVb 12/30/5/37, Barcelona Clinic B/C 33:51). Clinical...
Abstract Background and aims Lenvatinib, a newly developed molecularly targeted agent, has become available for patients with unresectable hepatocellular carcinoma (HCC). Neutrophil‐to‐lymphocyte ratio (NLR) been reported to be associated poor outcomes in numerous malignancies. In this study, we investigated the impact of NLR on associating HCC treated lenvatinib. Methods A total 237 lenvatinib were included. We performed univariate multivariate analyses cohort. addition, clarified...
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed elucidate early responses Atez/Bev. Methods From September 2020 April 2021, 171 u‐HCC patients undergoing Atez/Bev were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative and...
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of treated with Atez/Bev, especially CP-A and -B cases.From September 2020 March 2022, 457 u-HCC Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B 427:30, score [CPS] 5:6:7:8:9 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features...
To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab (Atez/Bev).A total of 249 HCC Atez/Bev were included. We analyzed survival and discontinuation this therapy cohort.Cumulative overall at 2, 4, 6, 8 months was 97.6%, 94.9%, 88.9%, 82.8%, respectively. Cumulative differed significantly between low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative...
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is important clinical issue. The present study aimed to elucidate the potential lenvatinib as a second-line option after Atez/Bev failure. Methods: From 2020 2022, 101 patients who received were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA)...
Background/Aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use tumor markers as biomarkers monitoring treatment response is necessary. This study aimed to elucidate changes positive rates 3 available Japan, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and lens culinaris agglutinin-reactive AFP (AFP-L3) uHCC...
We recently reported the real-world changes in etiologies of liver cirrhosis (LC) based on nationwide survey data and assessed LC with hepatocellular carcinoma (HCC).Fifty-five participants from 68 institutions provided 23,637 patients HCC-complicated LC. The changing trends were assessed. further analyzed 29 hospitals that annual number newly identified 2008 to 2016 (N = 9362) without any missing years transition real cases.In overall cohort, hepatitis C virus (HCV) infection (60.3%) B...
<b><i>Introduction:</i></b> The ALBI score is acknowledged as the gold standard for assessment of liver function in patients with hepatocellular carcinoma (HCC). Unlike Child-Pugh score, uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation. However, complex calculation limits its applicability. Therefore, we developed simplified based on data from large-scale HCC database.We used 5,249 naïve cases registered eight...